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1. Introduction 
Estrogen deprivation, for instance after ovariectomy or natural menopause, is associated 
with significant bone loss in adult women. (Lindsay, 1995)  Gonadotropin-releasing 
hormone agonist (GnRHa) inhibits hypothalamo-pituitary-gonadal hormone secretion and 
gradually reduces the estrogen level. (Wacharawsindhu et al., 2006) Consequently, 
decreases in bone mineral density, which are also observed after ovariectomy and natural 
menopause, have been observed during GnRHa therapy in women with endometriosis and 
men with benign prostatic hyperplasia. (Goldray et al., 1993)  Moreover, women who were 
treated with this analog showed body composition changes, including a decrease in lean 
mass and an increase in fat mass, which resemble the body changes that occur during the 
menopause. (Revila et al., 1998) 
Meanwhile, GnRHa has also been the treatment of choice for central precocious puberty 
(CPP) since the mid-1980s. (Crowley et al., 1981)  Many of the previous studies on the 
auxological effects of GnRHa treatment on CPP have focused on assessing the patient’s final 
height, whereas much less attention has been paid to changes in their weight and body 
composition. (Arrigo et al., 2004) 
However, concern has been expressed that CPP might be associated with increases in body 
mass index (BMI) both at the initial presentation and during GnRHa treatment (Boot et al., 
1998) and that individuals with the condition are prone to developing obesity. This concern 
is supported by adult cases that were treated with GnRHa, as described above.  
On the other hand, it is well known that BMI and percentage body fat increase during 
puberty. Consequently, gonadotropin-suppressive therapy can theoretically halt the 
progression to obesity by inhibiting pubertal development. 
Recently, there have been many reports about the changes in body composition that occur in 
children with CPP who are treated with GnRHa (Wacharsindhu et al., 2006, Arrigo et al., 
2004, Boot et al., 1998, Feuillan et al.,1999, Palmert et al., 1999, Chiumello et al., 2000, van der 
Sluis et al., 2002, Paterson et al., 2004, Oosdijk et al., 1996, Traggiai et al., 2005, Herger et al., 
1999, Pasuquino et al., 2008). Some reports have shown that obesity occurs at a high 
frequency among children with CPP (Arrigo et al., 2004, Feuillan et al., 1999, Palmert et al., 
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1999, Chiumello et al., 2000, van der Sluis et al., 2002, Paterson et al., 2004). However, most 
of these reports studied populations in Western countries, and almost none investigated 
Asian children (Wacharsindhu et al., 2006). Furthermore, in these studies, GnRHa was 
administered at higher doses (Boot et al., 1998, Chiumello et al., 2000, van der Sluis et al., 
2002) than are used in the standard gonadotropin-suppressive therapy protocol that is 
currently in operation in Japan. With some exceptions, all these reports showed that obesity 
is aggravated during GnRHa therapy (Wacharsindhu et al., 2006, Boot et al., 1998, 
Chiumello et al., 2000, van der Sluis et al., 2002, Paterson et al., 2004, Oosdijk et al., 1996, 
http://www.iotf.org/documents/iotfsocplan251006.pdf). Therefore, we assessed the effects 
of the standard gonadotropin-suppressive therapy protocol that is currently used in Japan 
on body composition in order to review the optimal dose of GnRHa. 
The aims of the present study were to prospectively evaluate whether obesity occurs at a 
high frequency among Japanese children with CPP and to longitudinally evaluate the body 
composition of Japanese children with CPP before and during GnRHa therapy.  
2. Subjects and methods  
2.1 Patients  
Eighteen patients participated in the study. At diagnosis, all of the patients had a history of 
increased growth velocity, breast development of Tanner stage 2 or more, and a bone age that 
was more than 1 yr above their chronological age. Ten girls had idiopathic central precocious 
puberty (ICPP), and 8 girls had idiopathic central early puberty (ICEP). The diagnosis of ICPP 
was made based upon the onset of breast development before the age of 7 yr and 6 mo, the 
generation of pubic hair before the age of 9 yr, or the onset of menses before the age of 10 yr 
and 6 mo, according to the diagnostic criteria currently used in Japan. ICEP was defined as the 
appearance of pubertal signs between 8 -10 yr of age. Furthermore, neither set of patients 
showed any evidence of hypothalamo-pituitary lesions on magnetic resonance imaging or 
additional conditions that might have affected their body mass index (BMI). 
The median age at the start of treatment was 8.3 yr (range: 6 to 11). All patients received 
leuprolide acetate (LUPRON DEPOT, Takeda, Osaka, Japan) at an initial dose of 30 g/kg, 
which was administered subcutaneously every 4 weeks according to the standard 
gonadotropin-suppressive therapy currently used in Japan.  
2.2 Methods  
Standard anthropometric measurements were taken at the baseline and during the 2-year 
GnRHa treatment period. BMI was calculated as weight (kg)/height (m2), compared with 
age- and sex-matched reference values, and expressed as a standard deviation score (SDS) 
according to the method of Inokuchi (Inokuchi, 2009). The percentage of overweight (POW) 
was calculated as 100 x (the measured weight – normal weight)/normal weight (%). Normal 
weight data were derived from the 1990 Ministry of Health and Welfare data (Yamazaki et 
al., 1994). A POW of ≥ 20% was considered to indicate obesity (Asayama et al., 2003). 
Pubertal development was determined according to the method of Tanner (Tanner & 
Whitehouse, 1976). 
Pituitary-gonadal axis function was considered to be adequately suppressed during 
treatment if the concentrations of LH and E2 were maintained within the prepubertal 
normal ranges of our laboratory; i.e., if a) the basal serum LH level was below 0.5 mIU/ml 
and b) the basal serum E2 level was below 10 pg/ml. In the patients that demonstrated 
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incomplete suppression, the dose of leuprolide acetate was increased to 150 g/kg. Bone age 
(BA) was assessed by one investigator using an x-ray of the left hand, according to the 
method of Greulich and Pyle (Greulich & Pyle, 1959). 
2.3 Statistical analysis 
For statistical purposes, the Wilcoxon test was used when appropriate in order to estimate 
the significance of differences between groups. The correlations between individual values 
were examined using Pearson’s test. All values are given as the mean ± S.E. The significance 
threshold was set at p < 0.05. 
3. Results 
3.1 Prevalence of obesity 
In our recent study of 18 girls with CPP or early puberty, five girls (27.8%) were diagnosed 
with obesity because their BMI values were higher than the 95th centile (Inokuchi, 2009) at 
the initiation of therapy. Moreover, the BMI standard deviation score (SDS) for 
chronological age (CA) was higher than zero in 14 (77.8%) patients, and the mean BMI SDS 
for CA was 1.07±0.32 at the baseline. Even when it was corrected for bone age (BA), the BMI 
SDS was still higher than zero in 9 (50.0%) patients, and the mean BMI SDS was 0.33±0.25 at 
the baseline. On the other hand, the POW was higher than 20% (indicating obesity) in 5 
patients (27.8%) at the baseline. 
3.2 BMI and POW during follow-up 
The mean BMI was significantly increased after 1 year and increased further afterwards 
(Fig.1). BMI was higher than the 95th centile in 5 patients (27.8%) at the initiation of therapy, 
which was also true after 2 years treatment.  
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Fig. 1. Changes in BMI during GnRHa therapy 
www.intechopen.com
 
Sex Steroids 
 
308 
The BMI SDS for CA was higher than zero in 14 patients (77.8%) at the initiation of therapy, 
which was also the case for 13 individuals (72.2%) after 2 years treatment. Furthermore, 5 
patients had BMI SDS of higher than 2 SD at the baseline, and 4 patients had BMI SDS of 
higher than 2 SD after 2 years treatment. The mean BMI SDS for CA was 1.07 ± 0.32 at the 
baseline and changed little during the therapy (Fig. 2).  
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Fig. 2. Changes in the BMI SDS for CA during GnRHa therapy 
On the other hand, the mean BMI SDS for BA was 0.33 ± 0.25 at the baseline and slightly but 
not significantly increased during the GnRHa therapy (Fig.3).  
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Fig. 3. Changes in the BMI SDS for BA during GnRHa therapy 
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In addition, the POW was higher than 20% (indicating obesity) in 5 patients (27.8%) at the 
baseline, which was also true after 2 yrs treatment. The mean POW was 8.2 ± 4.0% at the 
baseline and changed little during the GnRHa therapy (Fig. 4). 
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Fig. 4. Changes in POW during GnRHa therapy 
3.3 Correlation between the BMI SDS at the start of treatment and that during 
treatment for CA and BA 
Regression analysis showed that the BMI SDS for CA and BA at the start of treatment were 
positively correlated with those during treatment (Table 1, 2). 
 
 r 
After 6 months of therapy 0.963 
After 1 year of therapy 0.971 
After 2 years of therapy 0.975 
Table 1. Relationship among BMI SDS for CA during therapy 
 
 r 
After 1 year or therapy 0.947 
After 2 years of therapy 0.926 
Table 2. Relationship among BMI SDS for BA during therapy 
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4. Discussion 
Many reports have shown that obesity occurs at a high frequency among children with CPP. 
(Arrigo et al., 2004, Boot et al., 1998, Feuillan et al., 1999, Palmert et al., 1999, Chiumello et 
al., 2000, van der Sluis et al., 2002, Paterson et al., 2004)  Feuillan et al. reported that the 
mean BMI of 18 girls with precocious puberty due to hypothalamic hamartoma (HH) and 32 
with ICPP was higher than normal before GnRHa treatment (Feuillan et al., 1999), and 
Arrigo et al. reported that 23.6% of the 101 girls with ICPP that they studied were obese 
before the start of therapy. (Arrigo et al., 2004)  Our results confirm that obesity is a common 
problem in children with CPP in Japan. Indeed, in this study, a quarter of our patients were 
found to be obese according to both BMI and POW before the start of therapy. Moreover, 
the BMI SDS for CA and BA were higher than zero in more than half of the patients at the 
baseline. Since the prevalence of obesity in girls in later childhood is 14.3% in Japan 
(http://www.iotf.org/documents/iotfsocplan251006.pdf), the above figure indicates that 
the prevalence of obesity in children with CPP is unusually high.  
Although several reports have stated that obesity is a common problem in girls with CPP, as 
mentioned above, the reason why so many girls with CPP have an increased BMI is unclear. 
A decrease in lean body mass and an increase in fat mass leads to obesity. Chiumello et al. 
suggested that girls with CPP undergo a shortened period of prepubertal lean mass 
development and so possess an insufficient lean body mass, leading to obesity. (Chiumello 
et al., 2000)  Recently, Arrigo et al. hypothesized that the pre-treatment increase in BMI is 
caused pubertal hormonal changes and secondary changes in body fat rather than CPP 
itself, as in their series they found that the suppression of pituitary-gonadal axis function 
was accompanied by a significant decrease in excess weight (Arrigo et al., 2004). However, 
our results showed that the suppression of the pituitary-gonadal axis did not bring about a 
significant change in excess weight, as described below. Furthermore, as for the number of 
patients whose BMI SDS for CA was higher than zero, it decreased from 14 (77.8%) to 9 
(50%) after correcting for BA, and the mean BMI SDS for CA (1.07±0.32) also decreased to 
0.33±0.25 after correcting for BA at the start of treatment. Moreover, Oostdijk et al. reported 
that the BMI SDS for CA of CPP patients was higher than that of the reference population, 
whereas their BMI SDS for bone age (BA) was normal at the start of treatment. (Oosdijk et 
al., 1996)  Taken together, the BMI of children with CPP might be appropriate for the onset 
of adolescence, even though they are indicated to be overweight by BMI calculations. 
Therefore, it is reasonable to suggest that the pre-treatment overweightness observed in CPP 
girls is due to pubertal hormonal changes and secondary changes in body fat, rather than 
being a cause of their CPP.  
As for the progression of baseline overweightness in CPP patients, the available data in the 
literature are very inconsistent;  however, many reports have suggested that obesity 
progresses in this group (Wacharsindhu et al., 2006, Boot et al., 1998, Chiumello et al., 2000, 
van der Sluis et al., 2002, Paterson et al., 2004, Oosdijk et al., 1996, Traggiai et al., 2005). 
Oostdijk et al. treated 31 girls with CPP with triptorelin for a mean period of 3.4 years. 
(Oosdijk et al., 1996)  The mean BMI SDS for CA at the start of treatment was higher than 
that of the reference population, and it did not change significantly during treatment. 
However, the mean BMI SDS for BA at the start of treatment was normal and increased 
during treatment. Boot et al. treated 32 girls and 2 boys with CPP or early puberty with 
leuprolide-acetate for 2 years. (Boot et al., 1998)  Their lean tissue mass SDS decreased 
significantly during treatment, whereas their fat mass SDS and percentage body fat SDS 
www.intechopen.com
Standard Gonadotropin-Suppressive Therapy in Japanese Girls with  
Idiopathic Central Precocious or Early Puberty Does Not Adversely Affect Body Composition 
 
311 
increased. In addition, their mean BMI SDS was higher than zero at the baseline and 
increased during treatment. Chiumello et al. treated 14 girls and 2 boys with CPP with 
leuprolide and triptorelin for at least 1 year. (Chiumello et al., 2000) They concluded that fat 
mass is increased by GnRHa therapy and that this could lead to obesity; therefore, they 
suggested that CPP patients undergo a shortened period of pubertal lean mass development 
and that while the progression of puberty in these patients is associated with increases in fat 
and lean mass, only the latter is blocked by the “menopausal effect” or the GnRHa therapy 
itself. van der Sluis et al., who belong to the same group as Boot, reported 47 patients (36 
girls and 11 boys) with CPP or early puberty who received leuprolide-acetate for a mean 
period of 2.7 years. (van der Sluis et al., 2002) In this cohort, BMI SDS increased significantly 
during treatment, whereas lean body mass decreased significantly during treatment, and 
percentage body fat increased. Paterson et al. reported 46 girls with CPP or early puberty 
who received goserelin for a mean period of 1.6 years. (Paterson et al., 2004)  In this group, 
there was a marked increase in BMI following treatment. On average, the girls were fatter 
than the general population before treatment (BMI SDS: 0.93) and were significantly fatter 
(BMI SDS: 1.2) than the general population after the completion of therapy. Before 
treatment, 19 (41%) girls were overweight (BMI > 85th centile), 13 (28%) of whom were obese 
(BMI > 95th centile), which rose to 27 (59%) overweight patients, of whom 18 (39%) were 
obese, after the completion of therapy. Wacharasindhu et al. treated 10 Thai girls with CPP 
for a period of 1 year and reported that their percentage fat values increased significantly. 
(Wacharsindhu et al., 2006)  So far, this is the only report in an Oriental population. 
In contrast, some authors have reported no change throughout the observation period. 
(Palmert et al., 1999, Herger et al., 1999, Pasuquino et al., 2008) For example, Heger et al. 
treated 50 girls with CPP with depot triptorelin for a mean period of 4.4 years and reported 
that their BMI SDS values at pretreatment, at the end of treatment, and at final height were 
not significantly different. (Herger et al., 1999)  Palmert et al. treated 96 girls and 14 boys 
with CPP with deslorelin or histrelin for 36 months. (Palmert et al., 1999)  Among the girls, 
multiple regression analysis indicated that the BMI SDS for CA at the pretherapy visit was 
the greatest predictor of the BMI SDS for CA at the end of treatment. They concluded that 
the administration of GnRHa did not influence the progression of adolescent CPP patients 
toward obesity. Pasquino et al. reported 87 girls with CPP who received depot triptorelin for 
a mean period of 4.2 years. (Pasuquino et al., 2008)  Their BMI increased markedly during 
treatment, but their BMI SDS for CA did not change significantly. In addition, 14.3% of the 
girls were overweight and 9.1 % were obese at the start of therapy, and both categories 
contained 11.7% of patients at the discontinuation of treatment. Although the patients’ 
overall BMI increased, they remained in the same BMI centile and had the same BMI SDS 
throughout the treatment period. Regression analysis showed that the BMI SDS for CA at 
the end of treatment was positively correlated with the BMI SDS for CA at the start of 
treatment. As a result, they concluded that GnRHa treatment did not result in a significant 
BMI increase. 
On the other hand, Arrigo et al. reported 101 girls with CPP who received decapeptyl depot 
for over 2 years. (Arrigo et al., 2004)  As described above, a quarter of the girls were 
classified as obese at the start of therapy, and only 4% of them were still obese at the end of 
therapy. BMI SDS did not increase in any of the patients during the therapy period. In fact, 
both the mean BMI SDS and obesity prevalence significantly decreased during the treatment 
period. This is the only report to state that BMI and the prevalence of obesity decreased 
during GnRHa therapy. 
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In our study, although on the whole BMI increased, the SDS for both CA and BA remained 
the same throughout the treatment period. Moreover, POW also changed little during the 
therapeutic period, as reported by Chiumello (who described it as relative body weight) 
(Chiumello et al., 2000). It should be noted that we used a small amount of GnRHa in 
relation to body weight in accordance with the standard treatment protocol used in Japan, as 
described above (we used 2.5mg or less) and were able to control CPP. In the reports from 
Western countries in which the same leuprolide acetate drug was used, a dose of 3.75mg was 
used from the first stage onwards, and all showed a significant increase in BMI during 
treatment (Boot et al., 1998, Chiumello et al., 2000, van der Sluis et al., 2002). The doses used in 
other reports were also larger than the dose that is usually administered in Japan.  
In this study, regression analysis showed that the BMI SDS for both CA and BA during 
treatment were positively correlated with those observed at the start of treatment, as reported 
by Pasquino et al. (Pasuquino et al., 2008) and Palmert (Palmert et al., 1999). Therefore, we 
consider that the initial BMI SDS is a predictor of BMI SDS at subsequent visits. 
Taken together, the administration of GnRHa according to the standard Japanese protocol 
does not seem to influence the progression of children with CPP towards obesity. One 
possible reason for this is the suitability of the standard gonadotropin-suppressive therapy 
administered to girls with CPP in Japan, although racial differences might also be relevant.  
5. Conclusion 
In conclusion, the standard gonadotropin-suppressive therapy protocol used to treat girls 
with ICCP or ICEP in Japan does not adversely affect body composition, at least when 
administered for up to 2 years. 
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